CorestemChemon Inc.

CorestemChemon is a global biotechnology company specializing in stem cell-based drug development and non-clinical research. Committed to addressing unmet medical needs, the bio-pharmaceuticals division drives innovation in rare and incurable diseases. A key milestone in its efforts came in 2014 with the successful commercialization of Neuronata-R inj., a groundbreaking stem cell therapy for Amyotrophic Lateral Sclerosis (ALS). Building on this achievement, the division continues to develop treatments for rare and intractable diseases, including lupus, Neuromyelitis Optica (NMO), and multiple system atrophy (MSA). CorestemChemon’s non-clinical CRO division complements these efforts by offering world-class research services, including toxicity studies, pharmacokinetics analysis, safety pharmacology, and environmental toxicity testing. Operating under internationally recognized standards such as GLP and AAALAC accreditation, the division supports global drug development with innovative, high-quality solutions tailored to client needs. With a vision to rank among the world’s top 10 CROs, it strives to redefine research excellence in the industry. Together, these divisions embody CorestemChemon’s mission to lead biotechnology innovation and redefine what’s possible in healthcare.